GammaCan Appoints Dr. David Sidransky to Scientific Advisory Board; Oncologist
and Advisor to Biotechs to Provide Direction During Crucial Clinical Trial Phase
GIVAT SHMUEL, Israel, Apr 28, 2005 (BUSINESS WIRE) -- GammaCan International,
Inc. (OTCBB: GCAN), a developer of immunotherapies for cancer and other serious
conditions, today announced the appointment of Dr. David Sidransky to the
Scientific Advisory Board.
David Sidransky, M.D. is the Director of the Head and Neck Cancer Research
Division at Johns Hopkins University School of Medicine. In addition, he is
Professor of Oncology, Otolaryngology-Head and Neck Surgery, Cellular &
Molecular Medicine, Urology, Genetics, and Pathology at Johns Hopkins University
and Hospital. Dr. Sidransky is certified in Internal Medicine and Medical
Oncology by the American Board of Medicine. Dr. Sidransky has served as a
director of Imclone since January 2004. He is a founder of several private
biotechnology companies and has served on numerous scientific advisory boards of
many private and public companies, including Medimmune, Roche, and Amgen. He was
formerly on the board of scientific counselors at the NIDCR and a member of the
Recombinant DNA Advisory Committee at the National Institute of Health NIH
(RAC).
Dr. Sidransky sits on numerous editorial boards, has over 250 peer-reviewed
publications, and has contributed more than 40 cancer reviews and chapters and
also holds numerous issued biotechnology patents. He has been the recipient of
many awards and honors, including the 1997 Sarstedt International prize from the
German Society of Clinical Chemistry, the 1998 Alton Ochsner Award Relating
Smoking and Health by the American College of Chest Physicians and the 2004
Hinda and Richard Rosenthal Award from the American Association of Cancer
Research.
"Dr. Sidransky's wealth of experience in biotechnology and pharmaceuticals
ranging from his participation on scientific advisory boards and as a board
member coupled with his internationally recognized achievements in science, will
be of great value as GammaCan forges ahead with its recently announced Phase II
clinical trials," stated Dr. Dan J. Gelvan, CEO.
"Dr. Sidransky's acceptance of this appointment only reinforces our fervor to
bring the IVIg-based product through clinical trials to commercialization,"
Gelvan concluded.
Participation by Dr. Sidransky as a member of the Scientific Advisory Board does
not constitute or imply endorsement by the Johns Hopkins University or the Johns
Hopkins Hospital and Health System.
About GammaCan
GammaCan is focusing on the commercialization of a revolutionary anti-cancer
immunotherapy that the Company believes will be proven to be effective in
reducing the metastastic spread of a wide range of cancers. GammaCan's proposed
treatment is based in IVIg, a safe, relatively non-toxic human plasma-based
product, currently used to treat a variety of immune deficiencies and autoimmune
diseases. It works by strengthening the patient's immune system. Many experts
currently view immunotherapy as a future alternative to today's standard
chemotherapy. Approximately twenty companies produce IVIg, and annual worldwide
sales are currently in excess of 50 metric tons with an estimated value in
excess of 1.5 billion USD. IVIg is commonly used to treat certain autoimmune
diseases and blood disorders and to replace the antibodies in people who are
unable to produce them. For more information about Gammacan visit
gammacan.com or call the company's headquarters in Givat Shmuel,
Israel at 972-3-5774475.
SOURCE: GammaCan International, Inc.
CONTACT: DeMonte Associates
Investor Contact
Cynthia DeMonte, 212-605-0525
cdemonte@aol.com
demonte.com
. |
